On Wednesday, Legal Insurrection reported that the HHS has discontinued the Centers for Disease Control and Prevention (CDC) recommendations that children, teenagers, and pregnant women receive routine COVID-19 vaccinations. On Friday, the Food and Drug Administration (FDA) approved the Novavax Covid-19 vaccine with the unprecedented demand that Novavax conduct a new clinical trial of its shot after approval,
The article reports:
Health and Human Services Secretary Robert F. Kennedy, Jr., may be pulling ahead in the race to be the most active agency head during President Donald J. Trump’s second term.
Last week, Kennedy appeared before both the House Appropriations Committee and the Senate Health, Education, Labor, and Pensions (HELP) Committee and gave a masterclass in how to answer inane Democratic narrative-based questioning. He also ordered a review of abortion pill safety data, worried that the real statistics indicated more adverse effects than originally advertised.
Now, the HHS has discontinued the Centers for Disease Control and Prevention (CDC) recommendations that children, teenagers, and pregnant women receive routine COVID-19 vaccinations.
The article notes:
This marks a significant shift in federal health policy, moving away from the universal vaccination guidance that has been in place since September 2023. The new rules also promote a new framework for the testing of annual vaccines.
According to a report published Tuesday morning by The Associated Press, the Food and Drug Administration (FDA) would recommend annual booster shots for adults over the age of 65 in addition to younger adults and children whose pre-existing conditions or health concerns put them at greater risk of hospitalization or death from contracting COVID-19.
An article published on Tuesday by the New England Journal of Medicine provides a framework for developing and testing annual vaccines that might eventually be offered to generally healthy people who don’t fall into the currently recommended age and risk categories.
“For all healthy persons — those with no risk factors for severe Covid-19 — between the ages of 6 months and 64 years, the FDA anticipates the need for randomized, controlled trial data evaluating clinical outcomes before Biologics License Applications can be granted,” the article read. “Insofar as possible, when approving a Covid-19 vaccine for high-risk groups, the FDA will encourage manufacturers to conduct randomized, controlled trials in the population of healthy adults as part of their postmarketing commitment.”
These are welcome changes. Let’s go back to the day when parents decided what shots they or their children would receive.